Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01726699 · ClinicalTrials.gov registry record
Scripps Tumorgraft Study
A clinical trial of Solid Tumor Malignancy or Hematologic Malignancy, sponsored by Scripps Translational Science Institute.
- Completed
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT01726699: Completed study of Solid Tumor Malignancy or Hematologic Malignancy, sponsored by Scripps Translational Science Institute.
NCT01726699 is a study of Solid Tumor Malignancy or Hematologic Malignancy that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01726699, a study of Solid Tumor Malignancy or Hematologic Malignancy, has completed, sponsored by Scripps Translational Science Institute.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.
Conditions Studied
Study Locations (1)
California
- Scripps Translational Science Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-07 |
What the finished NCT01726699 record still lists
NCT01726699 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 1 condition, with Solid Tumor Malignancy or Hematologic Malignancy appearing as the primary indexed condition, and to 0 interventions.
NCT01726699 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01726699 about?
NCT01726699 is a clinical study titled "Scripps Tumorgraft Study". Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.
What is the current status of trial NCT01726699?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2012-11. Estimated completion is 2014-07.
What conditions does trial NCT01726699 study?
This clinical trial studies the following conditions: Solid Tumor Malignancy or Hematologic Malignancy.
Who is sponsoring clinical trial NCT01726699?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01726699 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia